Medicago truncatula Transcriptome or Gene expression

ABSTRACT: Our global transcriptomic approach to study Myc-LCO signalling in M. truncatula used an experimental design of three genotypes – A17 (WT), dmi3 and nsp1 – and three treatments – sulphated Myc-LCOs (S Myc-LCOs), nonsulphated Myc-LCOs (NS Myc-LCOs), and solvent controls (acetonitrile, ACN). We pooled two early treatment time points (2 + 4 h) based on preliminary data and reports of transcriptional changes occurring within hours of Myc-LCO treatment. Three biological replicates were sequenced per condition. We used M. truncatula dmi3 and nsp1 mutants, described originally as Nod−Myc− and Nod−Myc+, respectively, and the two major types of Myc-LCOs (sulphated and nonsulphated) to determine overlaps and specificities of Myc-LCO responses. Myc-LCOs were used at 10−6 M because they are biologically active at about a 100-fold higher concentration than Nod factors, which have been used at 10−7, 10−8 M in transcriptomic studies.

INSTRUMENT(S): Illumina HiSeq 2000

ORGANISM(S): Medicago truncatula

SUBMITTER: Clare Gough 

PROVIDER: E-MTAB-5182 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress